Trophos completes cardioprotective compound phase 1 study
The success could help make TRO40303 the first treatment to reduce cardiac reperfusion injury which leads to morbidity and mortality myocardial infarction. The study was aimed at assessing
WuXi XDC Cayman has signed an agreement to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 payload-linker technology platform for the development of an antibody-drug conjugate (ADC) candidate.